Nkarta to Participate in September Investor Conferences

Nkarta plans September 2026 fireside chats at H.C. Wainwright and Stifel conferences, with webcasts and 90-day replays on its investor site.

Rhea-AI Summary

Nkarta (NKTX) will participate in two investor conferences in September 2026, each featuring a fireside chat.

The company is scheduled for the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 10:30 a.m. ET and the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026, at 12:30 p.m. ET. Webcasts and replays of both events will be available in the Investors section of Nkarta’s website for approximately 90 days.

Argus 15 min delay

-3.26% vs previous close $2.81 last price 1.1x rel. volume Open Argus

Details

Market Reaction – NKTX

$2.80 $2.85 Day Range

$201.62M Market Cap

Following this news, NKTX has declined 3.26%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $2.81.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

allogeneic, CAR-NK

2 terms

allogeneic medical

"Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

CAR-NK medical

"The on-demand availability and outpatient dosing of our CAR-NK cells"

CAR‑NK are immune cells (natural killer cells) that have been genetically given a chimeric antigen receptor so they can home in on and destroy specific diseased cells, typically cancer. Think of it like equipping a guard with GPS coordinates for a target: it makes the cell better at finding and killing the enemy. Investors watch CAR‑NK programs because they offer potential for powerful, off‑the‑shelf therapies with different safety and manufacturing profiles than traditional drugs, which can drive company value but also carry clinical and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:

September 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
10:30 a.m. ET – fireside chat

September 23, 2026
Stifel 2026 Virtual Immunology and Inflammation Forum
12:30 p.m. ET – fireside chat

A simultaneous webcast of both events will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

FAQ

How can investors access Nkarta’s September 2026 conference presentations?

A simultaneous webcast of both fireside chats will be available in the Investors section of Nkarta’s website at www.nkartatx.com, and a replay of each event will be archived there for approximately 90 days.

When and where are Nkarta’s upcoming investor conference appearances?

Nkarta will appear at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, on September 16, 2026, at 10:30 a.m. ET, and at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026, at 12:30 p.m. ET.